Prozkoumejte nejčtenější články a videa na Campus Sanofi
In bullous pemphigoid, autoimmunity to BP180 and BP230 is thought to trigger a type 2 inflammatory response. Read this article to find out more
Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more
The management of bullous pemphigoid is challenging and new treatment approaches are needed. Read this article to find out more.